Keyphrases
Prediction Method
100%
Bevacizumab
100%
Survival Prediction
100%
High-grade Glioma
100%
MRI Diffusion
100%
Restricted Diffusion
57%
Diffusion-weighted Imaging
42%
Fainting
28%
Necrosis
28%
Viable Tumor
28%
Number of Patients
14%
Predictive Value
14%
Median Overall Survival
14%
Long-term Survival
14%
Result-oriented
14%
Log-rank Test
14%
Recurrence Rate
14%
Group by
14%
Group-based
14%
Potential Impact
14%
Recurrent Glioblastoma
14%
Kaplan-Meier Analysis
14%
Brain MRI
14%
Routine Care
14%
Institutional Review Board
14%
Survival Disparities
14%
Contrast-enhanced MRI
14%
Diffusion-weighted
14%
Tumor Spectrum
14%
Imaging Response
14%
Simultaneous Comparison
14%
Biochemistry, Genetics and Molecular Biology
Facilitated Diffusion
100%
Bevacizumab
100%
Diffusion Weighted Magnetic Resonance Imaging
100%
Survival Prediction
100%
Apparent Diffusion Coefficient
45%
Magnetic Resonance Imaging
36%
Prospective Study
9%
Overall Survival
9%
Retrospective Study
9%
Gadolinium
9%
Medicine and Dentistry
Bevacizumab
100%
Ganglioglioma
100%
Diffusion MRI
100%
Magnetic Resonance Imaging
50%
Neoplasm
25%
Necrosis
25%
Prospective Study
12%
Overall Survival
12%
Retrospective Study
12%
Recurrent Disease
12%
Kaplan Meier Method
12%
Log Rank Test
12%
Glioblastoma
12%
Neuroscience
Diffusion MRI
100%
Bevacizumab
100%
Magnetic Resonance Imaging
50%
Necrosis
25%
Immunology and Microbiology
Bevacizumab
100%
Apparent Diffusion Coefficient
62%
Magnetic Resonance Imaging
50%
Overall Survival
12%